Semaglutide

Details of the Concept

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist administered subcutaneously once weekly. It is approved at 1.0mg for type 2 diabetes management and at 2.4mg for chronic weight management in adults with overweight or obesity. It produces major, sustained weight loss through central appetite suppression and peripheral metabolic effects. In the cardiovascular space, semaglutide has become the first pharmacotherapy to demonstrate large, clinically meaningful benefit in patients with obesity-phenotype HFpEF.

Key Facts

Pharmacology

• GLP-1 receptor agonist; 94% sequence homology to native GLP-1; once-weekly SC injection
• Doses: 0.5mg or 1.0mg weekly (T2DM, Ozempic); 2.4mg weekly (obesity, Wegovy); dose escalation required over 16 weeks to minimize GI side effects
• Mechanisms: centrally reduces appetite; delays gastric emptying; promotes satiety; reduces body weight, systolic BP, CRP, and atherogenic lipids; likely has direct cardiac anti-inflammatory and hemodynamic effects

Weight Loss Efficacy

• STEP 1 trial (Wilding et al., NEJM 2021): 68-week treatment in adults with obesity (no T2DM); mean weight loss −14.9% with semaglutide vs −2.4% placebo
• In STEP-HFpEF: −13.3% vs −2.6% at 52 weeks (sources/semaglutide-stephfpef-nejm-2023, rating: very high)

STEP-HFpEF — Obesity-HFpEF (NEJM 2023)

• Population: 529 patients; HFpEF (LVEF ≥45%) + obesity (BMI ≥30) + no diabetes; 96 sites, 13 countries; 52 weeks
• Dual primary endpoints (both P<0.001):
  • KCCQ-CSS: +7.8 points (95% CI 4.8–10.9) — 4–15× larger than prior HFpEF pharmacotherapy trials (SGLT2i/sacubitril-valsartan/spironolactone: 0.5–2.3 points)
  • Body weight: −10.7 percentage points (95% CI −11.9 to −9.4)
• Confirmatory secondary endpoints (all P<0.001):
  • 6-minute walk distance: +20.3m (95% CI 8.6–32.1)
  • Hierarchical composite (death/HF events/KCCQ/6MWT): win ratio 1.72 (95% CI 1.37–2.15)
  • CRP: −43.5% vs −7.3% (treatment ratio 0.61)
• Exploratory: HF hospitalizations 1 vs 12 (HR 0.08); NT-proBNP fell despite weight loss
• Safety: Serious adverse events 13.3% vs 26.7% (P<0.001); cardiac events 2.7% vs 11.3% (P<0.001); GI AEs led to higher discontinuation in semaglutide arm (35 vs 14 total AE discontinuations)
  (sources/semaglutide-stephfpef-nejm-2023, rating: very high)

Mechanism of Benefit in HFpEF

• Weight loss with visceral adipose tissue reduction lowers blood volume, pericardial restraint, and ventricular interdependence
• NT-proBNP fell despite weight loss (normally rises with weight loss in obesity due to reduced clearance) — indicates genuine hemodynamic decongestion beyond simple weight reduction
• CRP reduction of 43.5% suggests potent anti-inflammatory effects targeting the systemic inflammatory substrate of HFpEF
• Lower AF/flutter events consistent with improved atrial hemodynamics and inflammation
• Authors conclude benefits reflect a combination of weight loss-mediated and direct drug mechanisms (sources/semaglutide-stephfpef-nejm-2023, rating: very high)

ESSENCE Phase 3 — MASH (NEJM 2025)

• Population: 800 adults with obesity and biopsy-confirmed MASH with moderate-to-advanced fibrosis (F2–F3); 72 weeks
• Superior to placebo on both histologic co-primary endpoints: resolution of MASH without worsening fibrosis AND ≥1 stage fibrosis reduction without worsening MASH
• 32.7% vs 16.1% had MASH resolution with concurrent fibrosis reduction (secondary endpoint)
• Limitation: In MASH-related compensated cirrhosis (phase 2b, n=71; 48 weeks), semaglutide reduced liver fat but did NOT reduce fibrosis or resolve MASH — efficacy appears limited to pre-cirrhotic disease
• Real-world data (GLP-1 RA vs DPP-4i or other glucose-lowering agents): lower risk of new-onset cirrhosis, hepatic decompensation, and HCC
  (sources/masld-nejm-2025, rating: high)

Cardiovascular Outcomes Trials — Injectable Semaglutide

• SUSTAIN-6 (T2DM, high CV risk; n=3,297; 2 years): Primary MACE HR 0.74 (P=0.02 for noninferiority; P=0.02 for superiority); nonfatal stroke HR 1.61 (NS)
• FLOW trial (T2DM + CKD; 2024): Primary composite kidney/CV events HR 0.76 (95% CI 0.66–0.88; P=0.0003) — first GLP-1 RA with nephroprotective evidence in CKD; baseline eGFR 47.0 ml/min/1.73 m²

PIONEER 6 — Oral Semaglutide Safety (NEJM 2019)

• Population: n=3,183; T2DM with high cardiovascular risk; median 15.8 months
• Primary endpoint: MACE HR 0.79 (95% CI 0.57–1.11) — noninferior to placebo; CV death HR 0.49 (95% CI 0.27–0.92) was the dominant directional signal
• Not powered for superiority; shorter follow-up; safety demonstration only

SOUL — Oral Semaglutide Cardiovascular Superiority (NEJM 2025)

• Population: n=9,650; T2DM (HbA1c 6.5–10%); age ≥50; ASCVD, CKD, or both; median 49.5 months; 444 sites, 33 countries; 26.9% on SGLT2i at baseline; baseline eGFR 73.8 ml/min/1.73 m²
• Oral semaglutide 14mg once daily (dose-escalated from 3mg; taken fasting)
• Primary MACE (3-point): HR 0.86 (95% CI 0.77–0.96; P=0.006) — first oral GLP-1 RA to achieve CV superiority
  • Nonfatal MI: HR 0.74 (95% CI 0.61–0.89) — dominant benefit
  • CV death: HR 0.93 (NS)
  • Nonfatal stroke: HR 0.88 (NS)
  • NNT at 3 years = 50 (95% CI 31–125)
• Major kidney disease events (confirmatory secondary; 5-point): HR 0.91 (95% CI 0.80–1.05; P=0.19) — not significant; hierarchy stopped
• Major adverse limb events: HR 0.71 (95% CI 0.52–0.96) — directionally positive; not formally tested (hierarchy stopped)
• Heart failure events: HR 0.90 (95% CI 0.79–1.03); all-cause mortality HR 0.91 (NS)
• HbA1c difference −0.56 pp; weight difference −2.95 kg; hsCRP 1.56 vs 2.01 mg/L at 104 weeks
• Serious AEs lower with semaglutide (47.9% vs 50.3%; P=0.02); GI discontinuations 6.4% vs 2.0%
• (sources/oral-semaglutide-soul-nejm-2025, rating: very high)

Comparison with Tirzepatide (SUMMIT, NEJM 2025)

• The SUMMIT trial tested tirzepatide (dual GIP/GLP-1 RA) in a similar obesity-HFpEF population but with longer follow-up (104 vs 52 weeks) and demonstrated for the first time a significant reduction in hard cardiovascular outcomes: composite CV death or worsening HF HR 0.62 (P=0.026)
• Tirzepatide achieved greater weight loss (−13.9% vs −10.7%) and similar KCCQ-CSS improvement (+6.9 vs +7.8 pts), suggesting that greater weight reduction translates to harder outcome benefits
• STEP-HFpEF HF hospitalisation reduction was exploratory only (HR 0.08; 13 events); SUMMIT was powered for and met this hard endpoint
• The addition of GIP receptor agonism in tirzepatide may provide additional anti-inflammatory benefit via GIP receptor expression in epicardial adipocytes — a mechanistic advantage not present with semaglutide
  (sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)

Contradictions / Open Questions

• Mechanism of benefit in HFpEF — weight loss vs direct drug effects: The NT-proBNP reduction despite weight loss suggests a hemodynamic benefit beyond weight loss alone, but the relative contributions of weight loss, anti-inflammatory effects, and direct GLP-1 receptor signaling cannot be disentangled from STEP-HFpEF alone. (sources/semaglutide-stephfpef-nejm-2023, rating: very high)
• Obesity paradox contradiction: STEP-HFpEF demonstrates that intentional pharmacologic weight loss benefits HFpEF patients — directly contradicting observational data suggesting weight loss is associated with worse HF prognosis (the obesity paradox). The distinction between intentional vs. unintentional weight loss is critical: prior negative observational data likely captured cardiac cachexia rather than therapeutic weight loss. (sources/semaglutide-stephfpef-nejm-2023, rating: very high)
• Durability beyond 1 year: No plateau observed at 52 weeks, but long-term data are absent. Whether benefits persist after drug discontinuation is unknown.
• Applicability to T2DM population: STEP-HFpEF excluded patients with diabetes. The ongoing STEP-HFpEF DM trial is evaluating semaglutide in obesity-HFpEF + T2DM with much higher SGLT2i use (32%), which will clarify benefit in the broader obesity-HFpEF population.
• Applicability to HFrEF: Whether semaglutide benefits patients with HFrEF + obesity remains unknown and is an important unanswered question.
• Mortality data (HFpEF): STEP-HFpEF was underpowered for clinical events (3 vs 4 deaths). The striking reduction in HF hospitalizations (1 vs 12) raises the question of whether longer, powered mortality trials would show survival benefit.
• SUMMIT (tirzepatide) achieved hard composite endpoint at 104 weeks — does duration explain the difference from STEP-HFpEF? STEP-HFpEF ran for 52 weeks with only exploratory HF event data (HR 0.08; 13 events). SUMMIT ran for a median 104 weeks and was powered for and met the composite endpoint (HR 0.62). Both drug and duration may explain the divergence — it remains unknown whether semaglutide over 2 years would demonstrate a similar hard outcome benefit. (sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)
• SOUL oral vs FLOW injectable — divergent kidney outcomes: SOUL (oral semaglutide 14mg; eGFR 73.8 at baseline) showed no significant kidney benefit (HR 0.91; P=0.19), while FLOW (injectable semaglutide 1mg weekly; eGFR 47.0) demonstrated significant kidney protection (HR 0.76; P=0.0003). This discordance is likely explained by: (1) the much lower baseline eGFR in FLOW (more room for measurable deterioration); (2) oral semaglutide bioavailability of only 0.4–1% vs injectable 89%. Whether the divergence reflects route-specific efficacy or population selection remains unanswered. (sources/oral-semaglutide-soul-nejm-2025, rating: very high)
• SOUL nonfatal MI as dominant MACE driver vs PIONEER 6 CV death as dominant signal: In SOUL (49.5-month median follow-up), nonfatal MI (HR 0.74) drove MACE benefit with no significant CV death reduction (HR 0.93). In PIONEER 6 (15.8 months), CV death reduction (HR 0.49) was the primary directional signal. This inversion likely reflects duration: early mortality benefit captures a different subset of at-risk patients than long-term atherosclerotic event prevention. (sources/oral-semaglutide-soul-nejm-2025, rating: very high)
• CV benefit without kidney benefit in SOUL — mechanism implications: The 14% relative reduction in MACE without significant kidney benefit challenges the assumption that GLP-1 RA cardiovascular and nephroprotective mechanisms are inseparable. The antiatherosclerotic mechanism (anti-inflammatory, LDL/weight reduction, MI prevention) may operate independently of the nephroprotective mechanism, which may require higher systemic drug exposure or more advanced baseline CKD to manifest. (sources/oral-semaglutide-soul-nejm-2025, rating: very high)

Connections

• Related to entities/HFpEF — primary therapeutic target; obesity-HFpEF phenotype
• Related to entities/Obesity — approved indication; foundational mechanism
• Related to concepts/Obesity-Paradox — STEP-HFpEF contradicts the paradox for intentional weight loss
• Related to concepts/Visceral-Adiposity — reduction in visceral fat as proposed primary mechanism
• Related to entities/Heart-Failure — emerging role across HF phenotypes
• Related to entities/Tirzepatide — class comparator; dual GIP/GLP-1 RA; SUMMIT achieved hard composite endpoint
• Related to entities/MASLD — ESSENCE phase 3 superior on both MASH histologic endpoints; GLP-1 RA class hepatoprotection
• Related to entities/Peripheral-Artery-Disease — SOUL: major adverse limb events HR 0.71 (directional benefit)
• Related to concepts/GLP-1-Receptor-Agonists — drug class; oral vs injectable formulation comparison; class CVOT data
• Related to sources/tirzepatide-hfpef-summit-nejm-2025 — SUMMIT RCT; comparative context

Sources

• sources/semaglutide-stephfpef-nejm-2023
• sources/tirzepatide-hfpef-summit-nejm-2025
• sources/masld-nejm-2025
• sources/oral-semaglutide-soul-nejm-2025